---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-25-000072"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:22:08.497407+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tandem Diabetes receives FDA 510(k) clearance for SteadiSet infusion set (3-day use); plans 7-day submission

## Summary
- FDA cleared SteadiSet infusion set for up to 3 days of use; submission by subsidiary CapBio.
- SteadiSet features integrated inserter with hidden needle for one-handed insertion; for adults with Type 1 diabetes.
- Tandem intends to submit separate 510(k) to extend use to up to 7 days; commercial activities delayed until clearance.
- No immediate revenue impact; commercial launch deferred pending 7-day clearance.

## SEC filing metadata
- accession: 0001438133-25-000072
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813325000072/0001438133-25-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813325000072/tndm-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-25-000072
- JSON: https://secwatch.observer/filing/0001438133-25-000072.json
- Plain text: https://secwatch.observer/filing/0001438133-25-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.